AAPL284.41+0.63 (+0.22%) ▲|ABBV251.15-2.21 (-0.87%) ▼|ABT93.54-0.58 (-0.62%) ▼|ACN129.55+0.57 (+0.44%) ▲|ADBE207.80+5.07 (+2.50%) ▲|AMAT658.51+31.67 (+5.05%) ▲|AMD526.32+4.74 (+0.91%) ▲|AMGN361.66+3.33 (+0.93%) ▲|AMT174.67-0.93 (-0.53%) ▼|AMZN240.66+7.97 (+3.43%) ▲|AVGO372.28+7.26 (+1.99%) ▲|AXP341.60+1.40 (+0.41%) ▲|BA218.56+1.38 (+0.63%) ▲|BAC58.13+0.32 (+0.54%) ▲|BKNG184.09+2.63 (+1.45%) ▲|BLK959.39-4.21 (-0.44%) ▼|BMY57.74+0.24 (+0.42%) ▲|BNY145.69+2.27 (+1.58%) ▲|BRK-B498.31+1.07 (+0.22%) ▲|C142.85+1.18 (+0.83%) ▲|CAT1,006.24+8.22 (+0.82%) ▲|CL92.23+0.17 (+0.18%) ▲|CMCSA25.49+2.32 (+9.99%) ▲|COF204.27+0.32 (+0.16%) ▲|COP105.80+0.10 (+0.09%) ▲|COST963.85+11.31 (+1.19%) ▲|CRM159.55+1.25 (+0.79%) ▲|CSCO116.65+2.88 (+2.53%) ▲|CVS103.67-0.65 (-0.62%) ▼|CVX170.72-0.19 (-0.11%) ▼|DE612.44-0.81 (-0.13%) ▼|DHR194.09-1.74 (-0.89%) ▼|DIS99.71+1.01 (+1.02%) ▲|DUK128.13-0.25 (-0.19%) ▼|EMR143.03-0.42 (-0.29%) ▼|FDX323.51+5.32 (+1.67%) ▲|GD349.37+2.66 (+0.77%) ▲|GE374.42+5.97 (+1.62%) ▲|GEV1,101.80+59.29 (+5.69%) ▲|GILD126.83-1.05 (-0.82%) ▼|GM77.91-0.18 (-0.23%) ▼|GOOG345.01+10.32 (+3.08%) ▲|GOOGL347.24+9.85 (+2.92%) ▲|GS1,035.93+16.32 (+1.60%) ▲|HD348.15-0.72 (-0.21%) ▼|HON248.86+5.45 (+2.24%) ▲|IBM271.02-0.61 (-0.22%) ▼|INTC124.03-4.30 (-3.35%) ▼|INTU275.49+7.77 (+2.90%) ▲|ISRG413.91+9.64 (+2.38%) ▲|JNJ254.70+0.04 (+0.02%) ▲|JPM330.35+1.30 (+0.39%) ▲|KO83.13+0.50 (+0.61%) ▲|LIN519.02-0.60 (-0.12%) ▼|LLY1,222.76+14.64 (+1.21%) ▲|LMT507.62+0.22 (+0.04%) ▲|LOW220.10-2.38 (-1.07%) ▼|LRCX389.88+10.79 (+2.85%) ▲|MA508.72+9.70 (+1.94%) ▲|MCD269.90+0.14 (+0.05%) ▲|MDLZ60.70-0.09 (-0.15%) ▼|MDT81.20+0.22 (+0.27%) ▲|META568.16+17.91 (+3.25%) ▲|MMM165.10+1.09 (+0.66%) ▲|MO73.65-0.14 (-0.19%) ▼|MRK128.07-0.59 (-0.46%) ▼|MS215.20+3.17 (+1.50%) ▲|MSFT379.04+6.07 (+1.63%) ▲|MU1,086.02-46.32 (-4.09%) ▼|NEE88.09-0.48 (-0.54%) ▼|NFLX75.47+1.66 (+2.25%) ▲|NKE41.13+0.38 (+0.92%) ▲|NOW101.84+3.50 (+3.56%) ▲|NVDA195.11+2.58 (+1.34%) ▲|ORCL152.60+4.07 (+2.74%) ▲|PEP140.79-0.60 (-0.42%) ▼|PFE24.35+0.06 (+0.23%) ▲|PG147.81-1.21 (-0.81%) ▼|PLTR118.08+5.15 (+4.56%) ▲|PM179.97-0.81 (-0.45%) ▼|QCOM190.75+1.36 (+0.72%) ▲|RTX188.95+0.96 (+0.51%) ▲|SBUX104.63+0.03 (+0.03%) ▲|SCHW91.02+0.35 (+0.38%) ▲|SO96.95-0.21 (-0.22%) ▼|SPG227.56+0.67 (+0.30%) ▲|T21.67-1.06 (-4.64%) ▼|TMO505.55-7.48 (-1.46%) ▼|TMUS175.99-6.69 (-3.66%) ▼|TSLA392.61+12.90 (+3.40%) ▲|TXN287.05+1.62 (+0.57%) ▲|UBER77.48+1.28 (+1.68%) ▲|UNH420.45-7.45 (-1.74%) ▼|UNP271.08+2.73 (+1.02%) ▲|UPS107.75-0.40 (-0.37%) ▼|USB61.07+0.16 (+0.26%) ▲|V342.34+6.11 (+1.82%) ▲|VZ44.07-2.48 (-5.32%) ▼|WFC84.07+0.21 (+0.25%) ▲|WMT116.13+0.44 (+0.38%) ▲|XOM136.37-0.18 (-0.13%) ▼|AAPL284.41+0.63 (+0.22%) ▲|ABBV251.15-2.21 (-0.87%) ▼|ABT93.54-0.58 (-0.62%) ▼|ACN129.55+0.57 (+0.44%) ▲|ADBE207.80+5.07 (+2.50%) ▲|AMAT658.51+31.67 (+5.05%) ▲|AMD526.32+4.74 (+0.91%) ▲|AMGN361.66+3.33 (+0.93%) ▲|AMT174.67-0.93 (-0.53%) ▼|AMZN240.66+7.97 (+3.43%) ▲|AVGO372.28+7.26 (+1.99%) ▲|AXP341.60+1.40 (+0.41%) ▲|BA218.56+1.38 (+0.63%) ▲|BAC58.13+0.32 (+0.54%) ▲|BKNG184.09+2.63 (+1.45%) ▲|BLK959.39-4.21 (-0.44%) ▼|BMY57.74+0.24 (+0.42%) ▲|BNY145.69+2.27 (+1.58%) ▲|BRK-B498.31+1.07 (+0.22%) ▲|C142.85+1.18 (+0.83%) ▲|CAT1,006.24+8.22 (+0.82%) ▲|CL92.23+0.17 (+0.18%) ▲|CMCSA25.49+2.32 (+9.99%) ▲|COF204.27+0.32 (+0.16%) ▲|COP105.80+0.10 (+0.09%) ▲|COST963.85+11.31 (+1.19%) ▲|CRM159.55+1.25 (+0.79%) ▲|CSCO116.65+2.88 (+2.53%) ▲|CVS103.67-0.65 (-0.62%) ▼|CVX170.72-0.19 (-0.11%) ▼|DE612.44-0.81 (-0.13%) ▼|DHR194.09-1.74 (-0.89%) ▼|DIS99.71+1.01 (+1.02%) ▲|DUK128.13-0.25 (-0.19%) ▼|EMR143.03-0.42 (-0.29%) ▼|FDX323.51+5.32 (+1.67%) ▲|GD349.37+2.66 (+0.77%) ▲|GE374.42+5.97 (+1.62%) ▲|GEV1,101.80+59.29 (+5.69%) ▲|GILD126.83-1.05 (-0.82%) ▼|GM77.91-0.18 (-0.23%) ▼|GOOG345.01+10.32 (+3.08%) ▲|GOOGL347.24+9.85 (+2.92%) ▲|GS1,035.93+16.32 (+1.60%) ▲|HD348.15-0.72 (-0.21%) ▼|HON248.86+5.45 (+2.24%) ▲|IBM271.02-0.61 (-0.22%) ▼|INTC124.03-4.30 (-3.35%) ▼|INTU275.49+7.77 (+2.90%) ▲|ISRG413.91+9.64 (+2.38%) ▲|JNJ254.70+0.04 (+0.02%) ▲|JPM330.35+1.30 (+0.39%) ▲|KO83.13+0.50 (+0.61%) ▲|LIN519.02-0.60 (-0.12%) ▼|LLY1,222.76+14.64 (+1.21%) ▲|LMT507.62+0.22 (+0.04%) ▲|LOW220.10-2.38 (-1.07%) ▼|LRCX389.88+10.79 (+2.85%) ▲|MA508.72+9.70 (+1.94%) ▲|MCD269.90+0.14 (+0.05%) ▲|MDLZ60.70-0.09 (-0.15%) ▼|MDT81.20+0.22 (+0.27%) ▲|META568.16+17.91 (+3.25%) ▲|MMM165.10+1.09 (+0.66%) ▲|MO73.65-0.14 (-0.19%) ▼|MRK128.07-0.59 (-0.46%) ▼|MS215.20+3.17 (+1.50%) ▲|MSFT379.04+6.07 (+1.63%) ▲|MU1,086.02-46.32 (-4.09%) ▼|NEE88.09-0.48 (-0.54%) ▼|NFLX75.47+1.66 (+2.25%) ▲|NKE41.13+0.38 (+0.92%) ▲|NOW101.84+3.50 (+3.56%) ▲|NVDA195.11+2.58 (+1.34%) ▲|ORCL152.60+4.07 (+2.74%) ▲|PEP140.79-0.60 (-0.42%) ▼|PFE24.35+0.06 (+0.23%) ▲|PG147.81-1.21 (-0.81%) ▼|PLTR118.08+5.15 (+4.56%) ▲|PM179.97-0.81 (-0.45%) ▼|QCOM190.75+1.36 (+0.72%) ▲|RTX188.95+0.96 (+0.51%) ▲|SBUX104.63+0.03 (+0.03%) ▲|SCHW91.02+0.35 (+0.38%) ▲|SO96.95-0.21 (-0.22%) ▼|SPG227.56+0.67 (+0.30%) ▲|T21.67-1.06 (-4.64%) ▼|TMO505.55-7.48 (-1.46%) ▼|TMUS175.99-6.69 (-3.66%) ▼|TSLA392.61+12.90 (+3.40%) ▲|TXN287.05+1.62 (+0.57%) ▲|UBER77.48+1.28 (+1.68%) ▲|UNH420.45-7.45 (-1.74%) ▼|UNP271.08+2.73 (+1.02%) ▲|UPS107.75-0.40 (-0.37%) ▼|USB61.07+0.16 (+0.26%) ▲|V342.34+6.11 (+1.82%) ▲|VZ44.07-2.48 (-5.32%) ▼|WFC84.07+0.21 (+0.25%) ▲|WMT116.13+0.44 (+0.38%) ▲|XOM136.37-0.18 (-0.13%) ▼|
27.6 C
New York
Monday, June 29, 2026

Tag: patients

newssourceFORcompanyinformationcontent1releasesmarket

UPDATE – Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference – The Sildenafil Cream That Raises the Bar

A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most

Foundation for Sarcoidosis Research Sarc Fighter Podcast Surpasses 100,000 Downloads, Amplifying Voices in the Sarcoidosis Community

Podcast dedicated to rare disease sarcoidosis hits 100,000 downloads.

Update On Clinical Trial Milestone – CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2...

SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce the successful completion of dose level 1 for its first-in-human Phase I dose-escalation clinical trial (NCT05302037) (“ANGELICA Trial”) for four late stage cancer patients and is scheduled to start dose level 2 of the ANGELICA Trial in third quarter of 2025.

Medtronic secures CE Mark for MiniMed™ 780G System for insulin-requiring people with diabetes including expanded indications in children as young as two, during pregnancy,...

GALWAY, Ireland, July 21, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in medical technology, today announced CE (Conformité Européenne) Mark in...

CLL Society Awards Research Projects Advancing CLL/SLL Care

2025 Research Program supports innovative studies aimed at improving outcomes and quality of life for CLL and SLL patients SAN DIEGO, July 21, 2025 /PRNewswire/...

MY DR NOW Adds Seventh Clinic in Mesa with Same-Day Healthcare

MESA, Ariz., July 21, 2025 /PRNewswire/ -- MY DR NOW, Arizona's largest independently owned primary care provider with 60 locations across the state, is...

Lifeist Wellness Expands Mikra’s Mind-First Product Portfolio with Three New Performance-Focused Formulations

New products reflect Mikra’s commitment to recently unveiled Mind-First Movement prioritizing mindset as the primary driver of peak performance

IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event

SOUTH SAN FRANCISCO, Calif., July 21, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and...

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1

– Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 – –...

West Welcomes Robert McMahon as Incoming Chief Financial Officer

EXTON, Pa., July 21, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced...

Canadians agree: fixing health care will help build stronger Canada

HUNTSVILLE, ON, July 21, 2025 /CNW/ - The Canadian Medical Association (CMA) is heading to Muskoka this week to remind Canada's leaders of the...

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias

AUSTIN, Texas, July 21, 2025 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first...

Darolutamide receives EU approval in third indication for patients with advanced prostate cancer

ORION CORPORATION
PRESS RELEASE
21 JULY 2025 at 10:30 EEST          

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease

Basel, 21 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) trials investigating astegolimab compared to placebo, on top of standard of care maintenance therapy in people with moderate to very severe chronic obstructive pulmonary disease (COPD). The studies included a broad population: both former and current smokers, regardless of blood eosinophil count, who have a history of frequent exacerbations.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatients

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers